Cortendo to raise about $33.2 mln in a private placement
Cortendo AB has agreed to raise about $33.2 million in a private placement. Investors in this round include Longwood Capital, TVM Capital, Granite Point Capital, RA Capital, New Enterprise Associates, Broadfin Capital and HealthCap. Also, Cortendo has agreed to buy Aspireo Pharmaceuticals’ Somatoprim, which is being studied in the treatment of acromegaly. The value of the acquisition is about $30 million. Headquartered in Göteborg, Sweden and with offices in Radnor, Pennsylvania, Cortendo is a biopharmaceutical firm focused on orphan endocrine disorders.
15 May 2015•4 mins read
